BSD Medical gets FDA nod for microwave ablation system
The FDA has granted BSD Medical, a developer of microwave systems used in the treatment of cancer, a 510(k) clearance to market its MicroThermX-100 microwave ablation system (MTX-100).
The system was developed to provide treatments as a standalone therapy, rather than only in combination with other therapies, according to BSD.
The Salt Lake City-base company said its MTX-100 is a compact, mobile system that includes a computer, a microwave generator, single-patient-use disposable applicators and a proprietary thermistor-based temperature monitoring system.
The MTX-100 provides minimally invasive access to the target tissue and can be used in open surgical as well as in percutaneous ablation procedures performed by both surgeons and interventional radiologists.
The system was developed to provide treatments as a standalone therapy, rather than only in combination with other therapies, according to BSD.
The Salt Lake City-base company said its MTX-100 is a compact, mobile system that includes a computer, a microwave generator, single-patient-use disposable applicators and a proprietary thermistor-based temperature monitoring system.
The MTX-100 provides minimally invasive access to the target tissue and can be used in open surgical as well as in percutaneous ablation procedures performed by both surgeons and interventional radiologists.